Scopus Biopharma Inc
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3s… Read more
Scopus Biopharma Inc (SCPS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.096x
Based on the latest financial reports, Scopus Biopharma Inc (SCPS) has a cash flow conversion efficiency ratio of 0.096x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.01 Million) by net assets ($-10.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scopus Biopharma Inc - Cash Flow Conversion Efficiency Trend (2017–2022)
This chart illustrates how Scopus Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Scopus Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scopus Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atesco Industrial Cartering JSC
VN:ATS
|
N/A |
|
FAN MILK LTD.
GSE:FML
|
N/A |
|
Pamtek Co. Ltd.
KO:271830
|
N/A |
|
RoboGroup T.E.K. Ltd
PINK:ROBOF
|
0.133x |
|
Otsuka Pakistan Ltd
KAR:OTSU
|
N/A |
|
46IE
LSE:46IE
|
N/A |
|
TAYLOR WIMPEY - Dusseldorf Stock Exchang
DU:TWW
|
N/A |
|
Chykingyoung Investment Development Holdings Inc
PINK:CHYI
|
1.284x |
Annual Cash Flow Conversion Efficiency for Scopus Biopharma Inc (2017–2022)
The table below shows the annual cash flow conversion efficiency of Scopus Biopharma Inc from 2017 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-7.06 Million | $-8.13 Million | 1.151x | +140.47% |
| 2021-12-31 | $4.02 Million | $-11.42 Million | -2.844x | -306.22% |
| 2020-12-31 | $-1.83 Million | $-2.53 Million | 1.379x | -94.61% |
| 2019-12-31 | $-82.86K | $-2.12 Million | 25.590x | -81.76% |
| 2018-12-31 | $-5.33K | $-747.32K | 140.315x | +6341.54% |
| 2017-12-31 | $101.59K | $-228.38K | -2.248x | -- |